Roche, Alnylam’s Zilebesiran meets primary endpoint in KARDIA-1 trial
Breaking news in the world of hypertension treatment, Roche and Alnylam Pharmaceuticals have announced the success of their Phase 2 study KARDIA-1. The investigational RNAi ... Read More